Nicotine-like e-cigarettes appear on the US market. FDA responds: We have reviewed their risks

Nicotine-like e-cigarettes appear on the US market. FDA responds: We have reviewed their risks

Previous research from Yale University has pointed out that some e-cigarettes contain nicotine analogs that may have unknown effects on health. These chemicals may have evaded FDA regulation and pose risks to adolescent brain development, learning ability and memory. The FDA said it will use all resources to protect the public, especially adolescents, from these potentially harmful addictive products.

According to Newsweek on August 12, a previous study from Yale University said that some e-cigarettes may contain nicotine-like chemicals with unknown effects on health.

These nicotine analogs interact with receptors in the brain without being restricted or reviewed by the FDA. As a result, these products are marketed as "flavors that appeal to teenagers" and avoid tobacco taxes.

An FDA spokesperson said these new chemicals may be more potent than nicotine and may affect adolescent brain development, learning ability and memory.

Jim McKinney, a public affairs specialist at the FDA, told Newsweek, "The FDA is looking at this from a whole-of-agency perspective and will continue to use all resources within its authority to protect the public, especially America's youth, from addictive products that can harm their health." McKinney noted that while more research is needed, some emerging data suggests these nicotine analogs may be more potent than nicotine, which is already highly addictive, and can alter adolescent brain development and have long-term effects. Nicotine analogs are chemicals that are structurally very similar to nicotine and therefore target the same receptors in the brain. Examples include 6-methyl nicotine and nicotinamide. A rat study showed that 6-methyl nicotine may be more toxic than nicotine. In addition, because these compounds are not subject to the strict restrictions of traditional nicotine, the ingredients listed on the label do not always match the actual ingredients in the product. Dr. Hanno Erythropel, a research scientist at the Yale School of Medicine, said in a statement, "To sum up, companies are actually trying to evade regulation when they launch new products with nicotine analogs with unknown health and addiction risks." In a study published in the journal JAMA Network, the scholar and his colleagues analyzed two e-cigarette and e-cigarette oil products on the market. The first product, Spree Bar, is labeled as containing 5% 6-methyl nicotine (50 mg/g), while the second product, Nic-Safe, was tested in four concentrations - 0, 12, 24 and 36 mg/ml. The results showed that both products were inconsistent with the ingredients stated on their labels. Spree Bar actually contained 90% less 6-methyl nicotine than advertised, while Nic-Safe contained low concentrations of 6-methyl nicotine without being clearly marked on the label (excluding the nicotinamide-free products tested). FDA spokesperson McKinney said,

"In general, the FDA does not comment on specific studies, but rather considers them as part of the evidence to further understand specific issues and help achieve its mission of protecting public health. Regarding nicotine analogs, the FDA is aware that there are companies that have reportedly been manufacturing products that may contain compounds that have chemical structures or properties that are different from nicotine."